3 results
Research question: Does oral administration with regulated release of 60 mg nifedipine a day reduce the symptoms of patients as determined in 1st. line health care, provided there is a good tolerancy of the medication.
Phase 1 • Primary objective: to determine the safety and tolerability, including the attenuation phenotype of a novel late-arresting GAP, named GA2 parasite, administered by sequentially increasing numbers of mosquito bites.• Secondary objective: to…
The primary objective is to demonstrate a difference in the proportion of patients with progressed/worsened disease state in patients receiving FX06 compared to patients receiving placebo until day 28.Assessment and treatment comparison of the…